Given that NF-κB plays a critical role in the activation of innate and adaptive immune responses, long-term use of pan-NF-κB inhibitors may not be desirable and may shift attention to emerging IKKα and NIK targeted kinase inhibitors and may prove to be very useful additions to the anti-cancer therapeutic armoury. The gene discussed is NFKB1; the disease is cancer.